BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16249885)

  • 1. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men.
    Hsu YH; Niu T; Terwedow HA; Xu X; Feng Y; Li Z; Brain JD; Rosen CJ; Laird N; Xu X
    Hum Genet; 2006 Jan; 118(5):568-77. PubMed ID: 16249885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women.
    Choi JY; Shin A; Park SK; Chung HW; Cho SI; Shin CS; Kim H; Lee KM; Lee KH; Kang C; Cho DY; Kang D
    Calcif Tissue Int; 2005 Sep; 77(3):152-9. PubMed ID: 16151677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Zhang LZ; Sun LH; Xu MY; Uitterlinden AG; Chen JL
    Osteoporos Int; 2005 Dec; 16(12):1519-24. PubMed ID: 15782282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
    Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women.
    Tu P; Duan P; Zhang RS; Xu DB; Wang Y; Wu HP; Liu YH; Si L
    Osteoporos Int; 2015 Jan; 26(1):179-85. PubMed ID: 25138264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men.
    Roshandel D; Holliday KL; Pye SR; Boonen S; Borghs H; Vanderschueren D; Huhtaniemi IT; Adams JE; Ward KA; Bartfai G; Casanueva F; Finn JD; Forti G; Giwercman A; Han TS; Kula K; Lean ME; Pendleton N; Punab M; Silman AJ; Wu FC; Thomson W; O'Neill TW;
    J Bone Miner Res; 2010 Aug; 25(8):1830-8. PubMed ID: 20205168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
    Zupan J; Mencej-Bedrac S; Jurković-Mlakar S; Prezelj J; Marc J
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women.
    Shang M; Lin L; Cui H
    Clin Biochem; 2013 Oct; 46(15):1493-501. PubMed ID: 23531404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
    J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.
    Whyte MP
    Ann N Y Acad Sci; 2006 Apr; 1068():143-64. PubMed ID: 16831914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
    Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
    J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
    Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
    Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
    Zheng H; Wang C; He JW; Fu WZ; Zhang ZL
    Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression.
    Takács I; Lazáry A; Kósa JP; Kiss J; Balla B; Nagy Z; Bácsi K; Speer G; Lakatos P
    Eur J Endocrinol; 2010 Feb; 162(2):423-31. PubMed ID: 19934266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density".
    Piedra M; García-Unzueta MT; Berja A; Paule B; Lavín BA; Valero C; Riancho JA; Amado JA
    BMC Med Genet; 2011 Dec; 12():168. PubMed ID: 22185226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.